NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM

BACKGROUND: Plexiform neurofibromas (PNs) can cause significant morbidity. In this phase 2 study, we assessed imaging and functional outcomes to the MEK-inhibitor Binimetinib in pediatric patients with PNs. METHODS: Children (age 1–17 years) with PN that were progressive or causing significant morbi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mueller, Sabine, Reddy, Alyssa T, Dombi, Eva, Allen, Jeffrey, Packer, Roger, Clapp, Wade, Goldman, Stewart, Schorry, Elizabeth, Tonsgard, James, Blakeley, Jaishri, Ullrich, Nicole J, Gross, Andrea, Walsh, Karin, Thomas, Coretta, Edwards, Lloyd, Prados, Michael, Korf, Bruce, Fisher, Michael J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Neurofibromatosis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715338/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.619
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados